Specialty· August 15, 2026 · 26 min read
Hidradenitis Suppurativa Access: Adalimumab Spread, Biologics, & Oral JAKs
By Ran Chen#Dermatology#Biosimilars#Interchangeability
Topic
IL-17 Inhibitor
Secukinumab, ixekizumab, bimekizumab, IL-17 pathway positioning, payer access, and immunology competition.
Evidence· June 19, 2026 · 13 min read
IL-17 and IL-23 biologics in FAERS: 400,283 adverse-event reports by the numbers
Evidence· June 13, 2026 · 11 min read
EULAR 2026 readouts: CD40L lupus win, IL-17 beats IL-23, off-the-shelf cell therapy
By Ran Chen#Immunology#Clinical Evidence#Pivotal Trials